#hybridoma

Immunological Applications

HAT medium contains:

HAT selective medium developed by John Littlefield in 1964 exploits metabolic auxotrophy to isolate somatic hybrids based on nucleotide salvage capability. Base medium DMEM or RPMI supplemented with fetal bovine serum provides carbon source, but three selective additives define HAT: hypoxanthine at 100 micromolar serving as purine base for salvage via hypoxanthine-guanine phosphoribosyltransferase converting to inosine monophosphate using phosphoribosyl pyrophosphate donor, thymidine at 16 micromolar supplying pyrimidine salvage substrate for thymidine kinase isoforms TK1 cytosolic and TK2 mitochondrial phosphorylating to thymidine monophosphate, and aminopterin at 0.4 micromolar acting as high-affinity folate antagonist. Aminopterin binds dihydrofolate reductase at picomolar Ki, preventing regeneration of tetrahydrofolate required for one-carbon transfer reactions in purine ring biosynthesis and thymidylate formation. De novo nucleotide synthesis collapses causing dNTP pool depletion, replication fork stalling,ATR mediated checkpoint activation, and S phase arrest. Only cells expressing both salvage enzymes bypass block by recycling exogenous bases, creating powerful negative selection for hybrids while eliminating auxotrophic myeloma background that lacks HGPRT.

Ref: Littlefield Science 1964 145:709 HAT selection; Szybalski Biochem Pharmacol HAT hypoxanthine aminopterin thymidine composition.

View Details

Immunological Applications

PEG (polyethylene glycol) is used in hybridoma technology for:

Efficient cell fusion must overcome hydration repulsion keeping lipid bilayers approximately two nanometers apart due to ordered water molecules bound to phosphatidylcholine headgroups. Polyethylene glycol with molecular weight 1450 to 4000 daltons is extremely hygroscopic linear polymer containing repeating ether oxygens that strongly bind water through hydrogen bonding, lowering water activity dramatically and creating osmotic stress that forces membranes into close proximity below one nanometer. At concentrated 40 to 50 percent weight per volume, PEG disrupts lipid packing, induces inverted hexagonal phase propensity, promotes hemifusion stalk formation between apposed outer leaflets as demonstrated by electron microscopy, then upon rapid dilution with serum-free medium stalk expands into fusion pore allowing mixing of cytoplasm, mitochondria, and endoplasmic reticulum. Unlike electrofusion requiring specialized cuvettes delivering kilovolt pulses or Sendai virus envelope hemagglutinin-neuraminidase introducing viral antigens that provoke immune response and hinder clinical use, PEG is chemically inert, inexpensive, and easily washed after one minute exposure. Cytotoxicity minimized by controlled exposure timing. Yield typically one stable hybrid per ten thousand B cells, sufficient selection amplifies later.

Ref: Lentz J Mol Biol PEG fusion membrane dehydration; Alberts MBoC membrane fusion hemifusion stalk; Nature Protocols PEG hybridoma.

View Details

Immunological Applications

The main purpose of using myeloma cells in hybridoma technology is:

Primary plasma cells cannot be cultured long term because they activate intrinsic mitochondrial apoptosis via Bim upregulation when removed from survival niche provided by stromal cell contact, interleukin-6, and BAFF, plus replicative senescence triggered by telomere shortening each division. Myeloma cells circumvent these barriers through multiple oncogenic lesions: expression of hTERT telomerase reverse transcriptase adding TTAGGG repeats preventing crisis, disruption of p53-MDM2 axis, loss of cyclin dependent kinase inhibitors p16 and p21, autocrine loops via IGF-1 and interleukin-6 constitutively activating JAK-STAT3, and anti-apoptotic proteins Bcl-2, Mcl-1, Bcl-xL sequestering Bax-Bak. Metabolically they exhibit enhanced aerobic glycolysis and glutaminolysis supporting high rate immunoglobulin synthesis of 20 to 50 picograms per cell per day needed for commercial manufacture. Specificity remains encoded entirely by B cell derived VDJ sequences while unlimited division derives solely from tumor genome. Without immortality contribution, antibody secreting clones exhaust after few doublings, master cell banking for regulatory filing impossible, and large-scale therapeutic production economically unfeasible, underscoring myeloma purpose for perpetuating culture.

Ref: Freshney Culture Animal Cells 7th ed myeloma immortality hTERT; Abbas Cellular Molecular Immunology hybridoma immortalization.

View Details

Immunological Applications

Hybridoma technology involves fusion of:

Hybridoma formation relies on merging two complementary cellular programs within one cytoplasm to create self-renewing antibody factory. Splenic B lymphocytes from immunized donor possess productively rearranged heavy chain locus on chromosome 14 with VDJ recombination mediated by RAG1/2 and light chain kappa or lambda locus with VJ recombination, encoding high-affinity combining site selected through germinal center affinity maturation involving activation-induced deaminase, but they senesce within days after extraction due to lack of telomerase, dependence on BAFF survival signal, and activation of mitochondrial apoptosis. Myeloma cells are malignant plasma cell tumors adapted to suspension culture, thriving in RPMI-1640 with 10 percent serum, exhibiting constitutively active PI3K-AKT, NF-kB, and c-Myc driving endless cell cycle progression bypassing G1/S checkpoint. When mixed at optimized ratio of one myeloma to five B cells and exposed to 50 percent polyethylene glycol 1450, plasma membranes dehydrate, outer leaflets merge forming hemifusion stalk, expansion creates fusion pore allowing cytoplasm mixing, endoplasmic reticula intermix, binucleated heterokaryons undergo mitosis to become mononucleated hybrids retaining immunoglobulin genes from B partner and proliferative machinery from tumor, describing core fusion of antibody-producing B cell and myeloma cell.

Ref: Janeway Immunobiology 9th ed monoclonal generation; J Genet Eng Biotechnol 2020 PMC7414427 hybridoma fusion B myeloma.

View Details

Immunological Applications

Monoclonal antibodies are produced by:

Mammalian antibody-secreting plasma cells are terminally differentiated, possessing an extensively expanded endoplasmic reticulum and unfolded protein response activated to sustain immunoglobulin production at up to 10,000 molecules per second, but these cells quickly trigger p53 dependent apoptosis and survive only days in vitro. To overcome limited lifespan, Georges Kohler and Cesar Milstein in 1975 created hybridoma technology that couples specificity donor with immortal partner. Splenic B lymphocytes isolated from hyperimmunized mouse provide functional heavy and light chain loci after somatic hypermutation and class switch recombination for high affinity binding. Murine myeloma lines like SP2/0-Ag14, NS0, and X63-Ag8.653 lack antibody secretion due to loss-of-function immunoglobulin genes but express constitutive telomerase, dysregulated N-Myc, loss of p16INK4a, autocrine IGF-1 signaling, and robust glycolytic metabolism supporting unlimited division in conventional media. Fusion using polyethylene glycol generates heterokaryons whose nuclei fuse, chromosome segregation yields stable hybrids secreting single idiotype. Cloning by limiting dilution at 0.3 cells per well ensures monoclonality, enabling establishment of master cell banks, GMP production, and consistent bioreactor harvests without repeated animal immunization.

Ref: Kohler & Milstein Nature 1975 256:495 hybridoma; Alberts Molecular Biology of Cell 6th ed Chapter 8 monoclonal production.

View Details

Immunological Applications

Monoclonal antibodies bind:

Bevacizumab recombinant humanized IgG1 mAb 149 kDa neutralizes soluble VEGF-A isoforms 121 165 189 206 secreted tumor stromal inflammatory cells hypoxia HIF1alpha binding hypoxia response elements driving transcription. VEGF-A binds VEGFR1 FLT1 and R2 KDR tyrosine kinases endothelial cells dimerization autophosphorylation Tyr1175 recruiting PLC gamma generating IP3 DAG increasing calcium PKC stimulating proliferation permeability via VE-cadherin internalization gaps survival Akt phosphorylation caspase-9. Binding epitope Arg82 Lys84 affinity 0.5 nM overlapping receptor binding interface prevents ligand engagement suppresses downstream ERK activation inhibits new capillary sprouting pruning immature vessels lacking pericyte expressing Ang2 and normalizes remaining vasculature reducing interstitial fluid pressure 20 to 5 mmHg improving perfusion enhancing penetration co-administered cytotoxic drugs fluorouracil irinotecan. Approved metastatic colorectal first-line chemotherapy showing improvement PFS 10.6 vs 6.2 months non-small cell lung glioblastoma exemplifying anti-angiogenic strategy targeting microenvironment rather malignant cells directly requiring exclusion bleeding risk hemoptysis bowel perforation management hypertension side effect class effect.

Ref: Ferrara NEJM Bevacizumab VEGF Targeted Therapy 2004; FDA Avastin Mechanism Label VEGF Neutralization; Lodish Angiogenesis VEGF Signaling Pathway Chapter 23.

View Details

Immunological Applications

Aminopterin in HAT medium functions by:

Antibody specificity arises exquisite three-dimensional complementarity between paratope heavy light chain variable domains epitope antigen surface determining binding free energy selectivity. Variable domains each contribute three complementarity-determining regions CDR1 CDR2 CDR3 loops supported conserved framework beta sheet Ig fold creating pocket groove protruding loop accommodating antigen features charged arginine aspartate hydrophobic tryptophan phenylalanine patches hydrogen bond donors carbohydrate. Binding stabilized hydrogen bonds CDR backbone carbonyl antigen side chain salt bridges arginine aspartate van der Waals contacts burying 600-900 square angstrom entropic gain displacing ordered water. Equilibrium dissociation constants after affinity maturation involving activation-induced cytidine deaminase mediated somatic hypermutation point mutations rate 10^-3 per base division selection improved binding germinal center dark zone light zone cycle follicular dendritic cell antigen presentation T follicular helper CD40 ligand signals reach picomolar 10^-11 M. Specific antibody discriminates closely related antigens differing single amino acid HER1 vs HER2 despite 40 percent homology or dopamine vs norepinephrine preventing cross-reactivity contributing safety therapeutic monoclonal targeting CD20 without depleting CD22 or HER2 without affecting EGFR. Specificity underpins diagnostic accuracy toxin neutralization blocking receptor interaction therapeutic targeting.

Ref: Janeway Antibody Specificity CDR Structure Affinity Chapter 5; NCBI Antibody Antigen Recognition Principles; Alberts Immunoglobulin Variable Region Specificity Chapter 24.

View Details

Immunological Applications

HAT medium contains:

HAT medium intelligent metabolic selection exploiting two distinct pathways nucleotide biosynthesis de novo synthesis requiring tetrahydrofolate one-carbon donor and salvage reusing preformed purines pyrimidines. Aminopterin potent folic acid analog competitively inhibits dihydrofolate reductase converting dihydrofolate tetrahydrofolate Ki 0.03 nM blocking regeneration tetrahydrofolate required thymidylate synthase converting dUMP dTMP purine enzymes GAR transformylase AICAR transformylase shutting de novo purine thymidine synthesis hours. Cell survival then depends entirely salvage enzymes HPRT converting hypoxanthine supplied IMP thymidine kinase phosphorylating thymidine TMP. Myeloma partners deliberately selected HPRT-negative mutants via resistance 8-azaguanine analog kills HPRT-proficient cells incorporating toxic nucleotide cannot utilize hypoxanthine therefore die aminopterin presence 48h. Primary B cells naturally expire short lifespan 3 days. Only heterokaryons inheriting functional HPRT gene B cell immortal proliferation program myeloma proliferate forming visible colonies 10-14 days post fusion counted inverted microscope. Optimized formulation hypoxanthine 100 uM aminopterin 0.4 uM thymidine 16 uM RPMI 1640 20 percent FBS supporting selective growth hybridomas.

Ref: Littlefield Science 1964 HAT Selection Classic; Janeway Immunobiology HAT Composition Components Chapter 2; Lodish Cell Culture HAT Selection Principle Media.

View Details

Immunological Applications

PEG (polyethylene glycol) is used in hybridoma technology for:

Polyethylene glycol polymer repeating ethylene oxide units average MW 1500 Da widely employed fusogen hybridoma generation due unique physicochemical properties affecting membrane biophysics. Mechanism involves strong hygroscopic nature binding water around phospholipid headgroups phosphatidylcholine sphingomyelin reducing hydration repulsion normally maintaining 2-3 nm separation bilayers enabling close apposition

Ref: Kohler Milstein PEG Fusion Method 1976 Detailed; Alberts Membrane Fusion PEG Mechanism Biophysical; Janeway Hybridoma PEG Fusion Laboratory Protocol Chapter 5.

View Details

Immunological Applications

The main purpose of using myeloma cells in hybridoma technology is:

Primary B lymphocytes after differentiation short-lived plasma cells produce Ig extraordinary rate but survive 3-5 days culture due activation-induced death mediated Fas upregulation after strong BCR crosslinking and lack telomere maintenance somatic cells lacking telomerase entering senescence limited divisions dependence extrinsic survival signals CD40L helper T cells cytokines IL-4 IL-6 IL-21 follicular helper. Continuous monoclonal manufacturing over months requires immortalization essential. Myeloma plasmacytoma malignant transformation plasma cells proliferate indefinitely without exogenous growth factors due translocation placing oncogene c-myc under IgH enhancer driving cyclin D and constitutive IL-6 secretion creating autocrine loop activating JAK-STAT pathway promoting survival proliferation. Fusion with B cell transfers transformation phenotype granting hybridoma sustained division >100 passages cryopreservation stability preserving viability liquid nitrogen storage ability grow serum-free chemically defined bioreactors scaled 2000 L robust ER comprising chaperone BiP protein disulfide isomerase folding heavy light chains efficiently. While antibody specificity derives entirely B-cell partner rearranged Ig loci longevity continuous secretion originate myeloma component overcoming natural mortality limitation enabling long-term production and banking hybridoma lines.

Ref: Kohler Milstein Myeloma Immortality Principle 1975; Lodish Hybridoma Immortalization Mechanism Biology; Janeway Myeloma Fusion Purpose Immunobiology Chapter 2.

View Details

Immunological Applications

Hybridoma technology involves fusion of:

Somatic cell fusion underlying hybridoma merges two differentiated cell types each contributing specialized traits necessary monoclonal antibody manufacturing. Antigen-experienced B lymphocyte harvested spleen four days after final booster carries functionally rearranged Ig heavy VDJ and light VJ genes formed RAG1/RAG2 recombination junctional diversity somatic hypermutation conferring high affinity specificity target epitope active transcription intronic enhancer Emu 3 prime regulatory region capacity synthesizing Ig up to 2000 molecules per second but limited lifespan due lack telomerase dependence T-cell help CD40L IL-4 IL-21 undergoing Fas-FasL activation-induced cell death few divisions. Plasmacytoma myeloma line P3X63Ag8.653 lacking HPRT enzyme secreting no endogenous Ig provides immortal growth due chromosomal translocation t(12;15) placing c-myc under IgH enhancer driving continuous cycle plus HAT selection sensitivity enabling elimination unfused myeloma. PEG induced membrane fusion allows cytoplasmic mixing forming heterokaryon subsequently nuclear fusion mitotic segregation retaining chromosomes encoding antibody variable regions B cell while myeloma chromosomes sustain uncontrolled proliferation. Selection eliminates unfused myeloma primary B cells permitting only hybridoma colonies producing monoclonal antibody exquisite specificity and immortality essential scale manufacturing.

Ref: Janeway Hybridoma Fusion B cell Myeloma Mechanism 9th ed; Alberts Cell Fusion Mechanism Chapter 19; NCBI Kohler Milstein Hybridoma Methodology Original.

View Details

Immunological Applications

Monoclonal antibodies are produced by:

Monoclonal antibodies originate immortalized hybridoma lines fusing single antibody-secreting B lymphocyte with myeloma partner preserving exactly one immunoglobulin gene rearrangement producing uniform paratope. Protocol begins immunization BALB/c mice purified antigen HER2 extracellular domain mixed Freund's adjuvant stimulating germinal center spleen. Four days after final booster splenocytes enriched plasma blasts expressing high-affinity surface IgG harvested. Fusion mediated PEG 1500 or electrofusion aligning cells pearl chains creates heterokaryons containing nuclei both parents tetraploid genome combining proliferative machinery myeloma P3X63Ag8U deficient HPRT and functional Ig heavy light chain variable regions B cell. Screening supernatants 10 days HAT medium ELISA identifies wells secreting antibody binding desired epitope single specificity affinity parent clone e.g., 10 nM. Cloning limiting dilution ensures monoclonality 0.5 cell per well. Resulting hybridoma inherits indefinite division activated c-myc autocrine IL-6 robust ER chaperone capacity folding continuous Ig secretion under Ig enhancers. Bioreactor expansion yields liters supernatant purified Protein A affinity chromatography producing uniform reagent defined sequence enabling therapeutics trastuzumab rituximab derived hybridoma technology now adapted recombinant CHO expression systems large-scale manufacturing.

Ref: Kohler and Milstein Nature 1975 Hybridoma Monoclonal Generation; Janeway Hybridoma Technology Production Chapter 5; Lodish Antibody Production Hybridoma Cells Method.

View Details